My NCBISign In

Display Settings:

Format

Send to:

Choose Destination
  • Your browser version may not work well with NCBI's Web applications. More information here...

PMC Biophys. 2009 Jun 26;2(1):5.

Structural and functional implications of p53 missense cancer mutations.

Tan Y, Luo R.

Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697-3900, USA. rluo@uci.edu.

ABSTRACT: Most human cancers contain mutations in the transcription factor p53 and majority of these are missense and located in the DNA binding core domain. In this study, the stabilities of all core domain missense mutations are predicted and are used to infer their likely inactivation mechanisms. Overall, 47.0% non-PRO/GLY mutants are stable (DeltaDeltaG < 1.0 kT) and 36.3% mutants are unstable (DeltaDeltaG > 3.0 kT), 12.2% mutants are with 1.0 kT < DeltaDeltaG < 3.0 kT. Only 4.5% mutants are with no conclusive predictions. Certain types of either stable or unstable mutations are found not to depend on their local structures. Y, I, C, V, F and W (W, R and F) are the most common residues before (after) mutation in unstable mutants. Q, N, K, D, A, S and T (I, T, L and V) are the most common residues before (after) mutation in stable mutants. The stability correlations with sequence, structure, and molecular contacts are also analyzed. No direct correlation between secondary structure and stability is apparent, but a strong correlation between solvent exposure and stability is noticeable. Our correlation analysis shows that loss of protein-protein contacts may be an alternative cause for p53 inactivation. Correlation with clinical data shows that loss of stability and loss of DNA contacts are the two main inactivation mechanisms. Finally, correlation with functional data shows that most mutations which retain functions are stable, and most mutations that gain functions are unstable, indicating destabilized and deformed p53 proteins are more likely to find new binding partners.PACS codes: 87.14.E-

PMID: 19558684 [PubMed - in process]

PMCID: PMC2709103

Supplemental Content

Click here to read Click here to read
Write to the Help Desk